📰 Precision Pairing News
Precision Pairing News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Precision Pairing. Real-time updates on events, politics, business and more.
February 29, 2024
Multiple members of management as expert speakers including Prof. Dr. Dolores Schendel, Chief Scientific Officer of Medigene, Dr. Barbara Lösch, Head of Technology & Innovation and Dr. Kirsty Crame, Vice
November 4, 2023
Planegg/Martinsried, November 4, 2023. Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors,
August 30, 2023
Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard) is an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors. Prof. Dolores
June 14, 2023
Planegg/Martinsried, June 14, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will be
June 13, 2023
Planegg/Martinsried, June 13, 2023. Medigene AG , an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will host an R&D Event... | June 13, 2023
May 30, 2023
Planegg/Martinsried, May 30, 2023. Medigene AG , an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will participate at the BIO... | May 30, 2023
May 22, 2023
Planegg/Martinsried, May 22, 2023. Medigene AG , an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announced today that the... | May 22, 2023
May 2, 2023
Press Release: Medigene expands end-to-end technology platform through worldwide, exclusive license of a CD40L-CD28 Costimulatory Switch Receptor further enhancing potential to treat solid tumors
May 2, 2023
Medigene accelerates the expansion of its end-to-end platform of multiple, combinable, exclusive and proprietary technologies with the potential to create best-in-class T cell receptor engineered T... | May 2, 2023
April 27, 2023
Martinsried/Munich, April 27, 2023. Medigene AG , an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will be presenting at the... | April 27, 2023